Fulvestrant is an oestrogen-receptor antagonist that exerts selective oestrogen receptor downregulation, antiproliferative activity and induction of apoptosis. It is indicated for the treatment of postmenopausal women with locally advanced or metastatic breast cancer for disease relapse or progression on or after adjuvant anti-oestrogen therapy. Fulvestrant was initially approved at a dose of 250 mg, however, the results of the CONFIRM trial led to approval of 500 mg dose (i.e. 500 mg on days 0, 14 and 28, then 500 mg every 28 days).
Therapeutic Place of Fulvestrant in the Management of

Hormone-receptor Positive Breast Cancer
Yogesh R Belagali, 1 Hanmant V Barkate, 1 Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. 1 More than 1.67 million cases of breast cancer were recorded in 2012, accounting for around 11.9% of all new cancer cases and 25.1% in women. 2 Oestrogen receptor-(ER)-positive breast cancer accounts for 75% of breast cancers in postmenopausal women. 3 Aromatase inhibitors (AIs) and anti-oestrogens are used in the adjuvant endocrine therapy of postmenopausal women with ER-positive breast cancer. AIs constitute the standard of care in the first-line management of patients with hormone-receptor positive breast cancer. 4 Both anastrozole and letrozole have proven superior to tamoxifen as five years' primary adjuvant therapy in early breast cancer, in addition to providing a number of tolerability benefits compared with the tamoxifen. 5 The selective oestrogen receptor modulator (SERM) tamoxifen is also used widely to treat both premenopausal and postmenopausal patients with advanced breast cancer as firstline treatment. 6 Other endocrine therapies include the progestins, such as megestrol acetate, high-dose oestrogens and androgens. However, these treatment options are being used less frequently as newer, more effective and better-tolerated therapies become available. Although adjuvant endocrine therapy is an effective treatment for breast cancer, most patients with advanced disease will eventually exhibit resistance to individual therapies. Nonetheless, an initial response to endocrine treatment is generally indicative of a positive response to further alternative endocrine agents. 7 Selective oestrogen receptor downreglators (SERDs) is a novel class of anti-oestrogens that differ from SERMs in being a full or 'pure' receptor antagonist. Fulvestrant is a SERD that competitively binds to oestrogen receptors (ER), with approximately 100-times greater binding affinity than that of tamoxifen. 8 Following binding to ER, fulvestrant blocks dimerisation of the receptor and limits its nuclear translocation. The fulvestrant-bound ER complex is unstable and more susceptible to degradation, resulting in downregulation of receptor expression. Fulvestrant also blocks the recruitment of both transcriptional activating factors (AF-1 and AF-2) to ER, which are needed for full activation of the transcription of ERregulated genes. In contrast, tamoxifen blocks recruitment of AF-2 only.
Hence, fulvestrant exhibits full ER antagonist activity, while showing no known oestrogen agonist activity. 9 It does not show cross-resistance with tamoxifen, or the oestrogen receptor agonist activity associated with tamoxifen. Fulvestrant has been shown to be active in patients with breast cancer previously treated with a SERM such as tamoxifen or with a non-steroidal anti-inflammatory (AI) such as anastrozole.
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Effect of fulvestrant on tumour receptors Robertson et 44 or matching tamoxifen placebo (n=43). Tumour biopsies taken prerandomisation and at surgery were compared.
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• ER downregulation: fulvestrant reduced the ER index in a dosedependent manner. The ER index was suppressed significantly by each of the three doses of fulvestrant (50 mg, 125 mg and 250 mg) when compared with placebo and by the highest dose of fulvestrant (250 mg) when compared with tamoxifen (p=0.024).
• Progesterone receptor (PgR) downreglation: a statistically significant and dose-dependent reduction in the PgR index was demonstrated for all doses of fulvestrant, whereas PgR levels increased after tamoxifen therapy, consistent with its partial agonist effects and the presence of a functional ER pathway. The decrease in the PgR index for the 125 mg and 250 mg doses of fulvestrant was also statistically significant, when compared with placebo.
• Ki67 downreglation: fulvestrant produced a dose-dependent reduction in Ki67 labelling. All three doses of fulvestrant significantly reduced the Ki67 index when compared with placebo and, to a similar extent, that seen with tamoxifen. Effect of fulvestrant on sex hormones, bone turnover markers and endometrial thickness There were no clinically significant changes in serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH) or sex hormone-binding globulin (SHBG). 13, 14 On the other hand, tamoxifen is associated with significantly (p<0.001) increased SHBG and decreased LH and FSH levels from baseline. 15 In a small study of 14 patients by Agrawal et al., patients with advanced breast cancer treated with fulvestrant 250 mg monthly up to 18 months were assessed for bone-specific turnover markers like serum bone-specific alkaline phosphatase (BAP), N-terminal propeptide of procollagen type 1 (PINP) and C-terminal telopeptide (CTX) at 0, 1, 6, 12 and 18 months. No clinically significant changes were observed in bone-specific turnover markers. 16 Also in the NEWEST trial, clinically significant changes were not observed with either the 250 mg monthly or 500 mg regimen up to 16 weeks. 17 A randomised, double-blind phase I study was conducted in healthy postmenopausal women to assess the effect of fulvestrant in the endometrium. 18 Thirty women were given a single intramuscular injection of fulvestrant 250 mg and endometrial thickness was measured on day 28. Mean endometrial thickness on day 28 was significantly lower in recipients of fulvestrant than in recipients of placebo (4.20 mm versus 11.22 mm; p=0.0001), following 14 days' treatment with ethinylestradiol.
Thus, there was lack of any agonist activity of fulvestrant in the endometrium of healthy postmenopausal women. Approximately 90% of fulvestrant is eliminated as metabolites in the faeces, with <1% excreted in the urine. Terminal elimination half-life of fulvestrant 500 mg regimen is 50 days for the 500 mg regimen.
Clinical pharmacokinetics
Alterations in special populations
Fulvestrant should be used with caution in patients with a creatinine clearance of less than 30 ml/min, however, no dosage adjustment is recommended in patients with creatinine clearance of >30 ml/min. The participants were randomised to receive either fulvestrant 500 mg intramuscularly on day 0, 250 mg on days 14, 28 and 250 mg every 28 days thereafter (n=351) or exemestane 25 mg orally was administered once daily (n=342). 10 Median TTP was 3.7 months in both groups (hazard ratio 0.963; 95% confidence interval [CI], 0.819 to 1.133; p=0.6531). The overall response rate (7.4% versus 6.7%; p=0.736) and clinical benefit rate (32.2% versus 31.5%; p=0.853) were similar between fulvestrant and exemestane, respectively ( Table 2) The results demonstrated that overall response rate (p=0.795) and clinical benefit rate (p=0.100) were similar between the two groups.
However, the 500 mg regimen demonstrated a significantly longer progression-free survival (PFS) than the 250 mg regimen (6.5 months versus 5.5 months, respectively; HR=0.80; p=0.006) ( Table 3) . 23 In the follow-up analyses, median OS was shown to be significantly longer with 500 mg of fulvestrant than with 250 mg (26.4 months versus 22.3 months; HR=0.81; p=0.016) ( Table 3) . 24 Following the publication of these results, fulvestrant at 500 mg has become the standard dose for this drug. The fulvestrant 500 mg arm demonstrated a statistically significant increase in the median time to progression and median overall survival (see Table 4 ). A consistent OS treatment effect was observed across predefined subgroups. This data supports superior efficacy of fulvestrant 500 mg over anastrozole as first-line endocrine therapy for postmenopausal women with hormone-receptor positive locally advanced or metastatic breast cancer. Although the results of the FIRST trial are encouraging, the definitive answer as to whether fulvestrant is the optimal first-line treatment will come from the ongoing placebocontrolled phase III FALCON trial that is randomising patients with oestrogen-receptor positive metastatic breast cancer to either 500 mg of fulvestrant or 1 mg of anastrzole. 27 Arakai et al. 28 reported a retrospective evaluation in 194 postmenopausal patients with recurrent/advanced breast cancer who received fulvestrant A meta-analysis of clinical benefit rates (CBR) for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, oestrogen-receptor positive advanced breast cancer evaluating five randomised controlled trials was presented by Robertson et al. 30 The results indicate that fulvestrant 500 mg is associated with a significant In a network meta-analysis comparing the efficacy of everolimus plus exemestane with that of fulvestrant 250 mg and 500 mg in the advanced breast cancer setting following adjuvant or first-line endocrine therapy, it was reported that that everolimus plus exemestane was more efficacious in terms of PFS/TTP than both fulvestrant 250 (HR=0.47) and 500 mg (HR=0.59). In the subgroup analysis of patients who received prior AI therapy everolimus plus exemestane was more efficacious for PFS/TTP than fulvestrant 250 mg and 500 mg (HR=0.47 and HR=0.55, respectively). 32 However, treatment related serious adverse events were lower in the patients on fulvestrant 500 mg than on exemestane plus everolimus (2.2% versus 11%).
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Fulvestrant in combination with other hormonal therapies
Preclinical data suggests that fulvestrant may be more effective in a low-oestrogen environment. 34 All the efficacy outcomes evaluated such as TTP, ORR, CBR, duration of response and OS were similar between both treatment arms (see Table 5 ).
The Southwest Oncology Group (SWOG) conducted a similar randomised phase III trial in which 707 postmenopausal women with hormone receptor-positive metastatic breast cancer, without prior chemotherapy or immunotherapy for metastatic disease, were randomised to fulvestrant plus anastrozole or anastrozole alone at the same doses as the FACT trial. 36 The median progression-free survival (PFS) was 15.0 months and 13.5 months in the combination and the anastrozole arms (p=0.007), respectively. In patients who did not receive prior tamoxifen therapy the differences were even higher (17.0 months versus 12.6 months HR=0.7; p=0.006), whereas in 280 women (40.3%) previously treated with tamoxifen, it did not achieve statistical significance (13.5 months versus 14.1 months, respectively; HR=0.89; p=0.37). OS was also longer in patients treated with the combination than in those who received anastrozole alone (47.7 months versus 41.3 months, respectively; HR=0.81; p=0.05), despite the fact that 41% of patients in the anastrozole arm crossed over to fulvestrant after progression ( Table 6 ).
The differences between trials could explain the discrepancy in results.
In the SWOG trial 40% of patients had prior exposure to adjuvant tamoxifen, whereas this percentage rose to 70% in the FACT trial.
Moreover, in the SWOG trial when patients were stratified according to prior tamoxifen exposure, only patients without previous tamoxifen showed statistically significant differences in terms of PFS.
Johnston et al. Cristofanilli et al. 38 reported final analysis of the a phase III study, PALOMA-3, involving 521 patients with advanced hormone-receptor positive breast cancer that had relapsed or progressed during prior endocrine therapy. Patients were randomised in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Overall, median PFS was longer for patients receiving the combination of palbociclib and fulvestrant versus fulvestrant alone (9.5 months versus 4.6 months; HR=0.46, p<0.0001); the patients receiving the combination had a 54% lower risk for disease progression. Most of the adverse events of grade 3 or 4 that occurred with the combination were neutropenia (65% versus 1% for fulvestrant); febrile neutropenia was uncommon.
Leukopenia also occurred at a greater frequency in patients receiving the combination (28% versus 2% for fulvestrant). On the basis of data from the PALOMA-3 study, the US Food and Drug Administration (FDA) expanded the use of palbociclib in combination with fulvestrant for the second-line treatment of advanced or metastatic breast cancer. 39 The recently presented FERGI trial 40 was the first randomised phase II study to evaluate the combination of ET with a PI3KCA inhibitor in 
Safety of fulvestrant
In the European and American trials (Trial 0020 and Trial 0021) that compared fulvestrant 250 mg with anastrozole, both treatments were well tolerated. [42] [43] [44] Anastrazole-receiving patients had a higher incidence of joint disorders, including arthralgia, arthrosis and arthritis Withdrawals due to drug-related adverse events were 0.9% and 1.2% in the fulvestrant arm and the anastrozole arm, respectively.
The CONFIRM trial showed that both doses of fulvestrant (250 mg and 500 mg) were well tolerated with no substantial differences in the incidence and severity of prespecified adverse events. There were no significant differences in the quality of life between both dosages. 23 The FIRST trial showed that fulvestrant 500 mg was well tolerated with an adverse events profile comparable to that of anastrozole and consistent with that previous evidence. 12, 23, 25 The incidence of serious adverse events was 11.9% versus 9.7% with fulvestrant 500 mg and anastrozole, respectively. The most common adverse events in the fulvestrant 500 mg arm were bone pain (13.9%), nausea (10.9%), arthralgia (9.9%), constipation (9.9%), vomiting (8.9%) and dyspnoea (8.9%). The incidence of arthralgia was similar between the two arms, but headache and asthenia were less frequent in the fulvestrant arm.
In a meta-analysis by Telford 31 Other trials, such as the EFECT and the FACT trials, showed no differences in terms of safety data of fulvestrant in comparison with the control drugs. 10, 26 Only the FACT trial showed a higher incidence of hot flashes in the combination arm compared with the single treatment arm (p=0.003).
In general, fulvestrant is well tolerated, with very low frequency of treatment dropout. In addition, there were no significant differences between the toxicity profiles of fulvestrant and other hormonal therapies such as anastrozole, tamoxifen and exemestane, or between both doses of fulvestrant in the treatment of hormone-sensitive advanced breast cancer.
Current role of fulvestrant in therapy and guideline recommendations
The clinical efficacy of fulvestrant in postmenopausal women with hormone receptor-positive metastatic breast cancer who had progressed on prior anti-oestrogen therapy was established for a 250 mg once-monthly regimen by a retrospective analysis of combined data from two large randomised trials (0020 and 0021). Endocrine agents in monotherapy demonstrated high efficacy and tolerability, but endocrine resistance commonly arises. Currently, there is an urgent need to develop predictive tools or markers that can reliably identify patients who will benefit from endocrine therapy alone and those that will require different approaches, such as poly-endocrine therapy or combination with targeted agents. Studies investigating poly-endocrine therapy are contradictory and need further validation.
Numerous new agents in combination with endocrine therapy are in clinical development for patients with HR-positive advanced breast cancer. However, while considering such combination therapy, any additional benefit should be carefully weighed against additional toxicity and costs. n
